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Abstract
This study compared color appearance data for two populations of middle-aged women: (1) women using the selective estrogen recep-
tor modulator tamoxifen as adjuvant therapy following successful treatment for early-stage breast cancer, and (2) healthy amenorrheic
(peri- or post-menopausal) control subjects not using any hormonally acting medications. A 3-alternative forced-response paradigm (with
“blue”, “lavender”, or “white” as the allowable responses) was used for assessing the perceived color of 440-nm foveal test stimuli super-
imposed on a larger 3.6 log td 580-nm background. In contrast to the control subjects, the majority of tamoxifen users described the test
stimuli as “white”, whether at threshold or slightly suprathreshold. Threshold-sensitivity measurements themselves appeared less eVective
for distinguishing between subject groups. The results show that a simple color-naming procedure can reveal alterations of foveal short-
wavelength-sensitive cone-mediated visual function that are common among tamoxifen users.
 2005 Elsevier Ltd. All rights reserved.
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Tamoxifen is a selective estrogen receptor modulator
(SERM) that is used as adjuvant therapy for early-stage
breast cancer (Clemons, Danson, & Howell, 2002). Tamoxi-
fen is known to occasionally cause changes in visual func-
tion that lead patients to seek ophthalmologic care,
whereupon conventional ophthalmoscopic techniques can
reveal pathologic changes at the retina or optic nerve head
(Gorin et al., 1998; NayWeld & Gorin, 1996; Noureddin
et al., 1999; Pavlidis et al., 1992). However, two studies have
reported the existence of visual change that is relatively
common but also relatively subtle, and that, furthermore,
occurs prior to or independent of intraocular change that
would be evident ophthalmoscopically at a patient’s initial
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doi:10.1016/j.visres.2005.11.003presentation (Eisner, Austin, & Samples, 2004a; Gorin
et al., 1998).
The Wrst study reporting subclinical visual-function
change was conducted by Gorin et al. (1998). Gorin et al.
(1998) used a desaturated D-15 test and found that the
color discrimination of women who had used tamoxifen for
many years tended to be slightly worse than the color dis-
crimination of women who had never used tamoxifen. They
also found reduced color discrimination for former long-
term tamoxifen users as well.
Subsequently, Eisner et al. (2004a) reported that tamoxi-
fen users had changes of visual function involving the
responses of short-wavelength-sensitive (SWS) cones, which
are important for color vision (Calkins, 2001). Eisner et al.
(2004a) measured visual thresholds to short-wavelength test
stimuli presented on yellow backgrounds that caused these
visual thresholds to be mediated via the response of SWS
cones. The strongest eVect occurred in the visual-Weld periph-
ery, where long-term tamoxifen users were found to have rel-
atively low SWS-cone-mediated sensitivity. There was
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fovea, but the eVects were weak. This could mean either that
(1) foveal visual response is aVected relatively little among
tamoxifen users, (2) the foveal stimulus parameters were not
well suited for revealing visual change among tamoxifen
users, or (3) the threshold methodology was not optimal for
detecting changes in foveal response.
The rationale for the study by Eisner et al. (2004a) was
based on two pieces of information: (1) the inference that
tamoxifen could aVect color vision, as reported by Gorin
et al. (1998), and (2) the knowledge, based on previous stud-
ies by Eisner and colleagues (Eisner, 1993; Eisner, Samples,
Campbell, & CioY, 1995), that middle-aged or elderly
women sometimes describe the color appearance of short-
wavelength test stimuli at threshold as white when these
stimuli are presented on yellow backgrounds that light-
adapt the retina. Corresponding age-related color appear-
ance changes were found to occur only infrequently for
men, who generally described these short-wavelength test
stimuli as lavender in a forced-response paradigm (Eisner,
1993; Eisner et al., 1995), consistent with an SWS cone con-
tribution to blueness and redness (Shinomori, Spillmann, &
Werner, 1999; Wei & Shevell, 1995). These results suggested
that gender-dependent color-appearance changes might
reXect age-related changes in female hormonal function.
The present study took into account the results of Gorin
et al. (1998), together with the various sets of results by Eis-
ner and colleagues (Eisner, 1993; Eisner et al., 1995, 2004a).
We sought to determine whether tamoxifen users, particu-
larly long-term tamoxifen users, were more likely than
other women to perceive short-wavelength test stimuli as
white when these stimuli were presented on moderately
bright yellow backgrounds that caused these stimuli to be
detected via SWS cones.
Thus, the present study reports the results of color-nam-
ing data obtained using the same type of forced-response
paradigm used previously for revealing gender-dependent
eVects (Eisner, 1993; Eisner et al., 1995). Because women’s
natural menstrual cycles can inXuence SWS-cone-mediated
response (Eisner, Burke, & Toomey, 2004b), and because
tamoxifen users often become amenorrheic (Mourits et al.,
2001), all data for this report were from subjects who had
not experienced menses for at least 6 months at the time of
testing. In addition, none of the control subjects was using
any hormonally acting medications, such as oral contracep-
tives or estrogen replacement.
2. Methods
2.1. Subjects
Subjects were recruited from two populations of women ages 40–69
years old: (1) women using the standard dose of 20 mg tamoxifen daily as
adjuvant therapy after successful treatment for early-stage breast cancer
(tamoxifen users), and (2) healthy women not using any hormonal medica-
tions (control subjects). Tamoxifen users were assigned to one of two
groups, short-term users and long-term users, according to their duration
of tamoxifen use. A 2-year cutoV was used for distinguishing short-termusers (62 years) from long-term users (>2 years). The choice of a 2-year
cutoV was made prospectively based on previously published visual-Weld
data (see Fig. 2 in Eisner et al., 2004a) that indicated a fairly sharp delinea-
tion for tamoxifen-associated changes of SWS-cone-mediated response.
We adopted a cutoV of “less than or equal to 2 years” because a 4-month
gap existed between 2 years and the next highest duration of use for sub-
jects enrolled in the present study.
All subjects met a set of criteria for excellent ocular health, which have
been described previously (Eisner et al., 2004a; Eisner & Samples, 2003).
The functional criteria included 20/20-or-better acuity in the test eye and
no worse than 20/25 acuity in the fellow eye, and normal color vision in
each eye (i.e., no more than a single minor transposition error on the D-15
test conducted under Macbeth illumination (Adams, Rodic, Husted, &
Stamper, 1982)). All tamoxifen subjects were fully active and able to carry
on all pre-cancer activities without restriction. No subjects were known to
have cancer at the time of testing, none of the control subjects had ever
used tamoxifen, and none of the tamoxifen users was using any other
hormonally acting medication.
Data are reported for 32 control subjects, 30 short-term tamoxifen
users, and 24 long-term tamoxifen users. The average age of these control
subjects was 57.5 (SD D 6.7) years, the average age of these short-term
tamoxifen users was 54.2 (SD D 5.4) years, and the average age of these
long-term tamoxifen users was 57.7 (SD D 6.9) years.
All subjects were unpaid volunteers. Most subjects responded to
recruitment ads specifying the requirement of “normal reading vision (cor-
rective lenses OK)”. These ads were placed on electronic sites or in loca-
tions where breast cancer survivors speciWcally or women in general
receive health information or health care. Ads were also placed in the local
newspaper, and on the Oregon Health & Science University (OHSU) web-
site for study opportunities. Some subjects were referred by subjects tested
previously.
2.2. Procedures
2.2.1. Subject screening and other non-Maxwellian-view procedures
Screening and training procedures have been described previously (Eisner
& Samples, 2003; Eisner et al., 2004a). Additional procedures (Eisner,
Incognito, Toomey, O’Malley, & Samples, 2005) that were conducted after
the color-naming procedures are not reported here. All portions of the study
adhered to the tenets in the Declaration of Helsinki and were approved by the
OHSU Institutional Review Board and the OHSU Cancer Institute. Written
informed consent was obtained from all subjects before testing.
2.2.2. Maxwellian-view threshold measurements
A series of foveal increment-threshold measurements were obtained
for a series of test/background stimulus combinations. The apparatus and
its calibration have been described previously (Eisner, 1986), although an
eye-piece/chin-rest assembly (Eisner & Samples, 2003; Eisner et al., 2004a)
was used rather than a bite-bar for the present study.
All background stimuli were 11° diameter disks. Subjects were
instructed to Wxate the center of these disks. Fixation was aided by a set of
diagonal crosshairs with a 4° central gap. Test stimuli were 3° diameter
disks that were centered inside the background crosshairs and square-
wave modulated at 1.5 Hz with a 50% duty cycle. The test stimuli were pre-
sented continuously.
Thresholds were obtained using a method of ascending limits, in which
the subject signaled when the test stimulus Wrst became visible. All thresh-
old data for this paper were obtained for steady-state adaptation condi-
tions, in which case the incremental step size was 0.06 log unit, and
threshold was computed as the mean of four responses for each test/back-
ground stimulus combination.
Steady-state thresholds were measured on each of three diVerent
580-nm background Welds—2.0 log td, 1.6 log td, and 3.6 log td, in this
order—using test wavelengths and adaptation periods described previ-
ously (Eisner & Samples, 2003). SWS-cone-mediated thresholds were mea-
sured at 440 nm, and veriWcation of SWS-cone isolation at 440 nm was
made by comparing 440-nm thresholds with 490-nm thresholds (Eisner
et al., 1995).
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Immediately after the Wnal threshold setting was made for the 440-nm
test stimulus on the 3.6 log td 580-nm background and before this setting
was changed, subjects were asked, “If you had to choose, which of the fol-
lowing three colors best describes the test light: blue, lavender, or white?”
After each subject gave her response, the test-stimulus illuminance was
raised 0.2 log units, and the same question was asked again.
3. Results
This section is divided into two parts. The Wrst part
reports the numbers of subjects in each group (control sub-
jects, short-term tamoxifen users, and long-term tamoxifen
users) who described the 440-nm test stimulus as “blue”,
“lavender”, or “white” at threshold and at suprathreshold.
The second part compares color-naming responses with
threshold measurements of SWS-cone-mediated response.
3.1. Numbers of subjects using the diVerent color names
Of all the subjects tested, only 2 chose “blue” to best
describe the threshold-level 440-nm stimulus. One of these
2 subjects was a short-term tamoxifen user, and the other
was a control subject. However, because the 440-nm sensi-
tivity for this tamoxifen user was clearly abnormal, being
more than 1.5 log units below the corresponding sensitiv-
ity of every other subject tested with the 3.6 log td back-
ground, her data are excluded from all subsequent
analyses. The sensitivity data for the other “blue-naming”
subject did not appear to be abnormal. Nevertheless, her
data likewise are excluded from further color-naming
analyses, since grouping her data with the data from the
other “non-white-naming” control subjects would only
strengthen the results. That is, signiWcant p values would
be considered even more signiWcant were this subject’s
data included.
The proportions of subjects who chose either “white” or
“lavender” to best describe the threshold-level stimulus are
shown in Fig. 1A. Among control subjects, there were 13
white-namers and 18 lavender-namers; among short-term
tamoxifen users, there were 16 white-namers and 13 laven-
der-namers; and among long-term tamoxifen users, there
were 21 white-namers and only 3 lavender-namers. The rela-
tive proportions of white-naming subjects diVered signiW-
cantly among the 3 groups (pD0.001, likelihood ratio
2 D13.24, df D2), as assessed using a log-linear model with
the interaction term omitted. By partitioning the likelihood
ratio 2 statistic, G2(T), naturally into 2 separate components
via decomposition of the original table T into 2 subtables (T1
and T2) such that G
2(T)D G2(T1) +  G2(T2), it is possible to
conclude more speciWcally (a) that the proportion of subjects
who chose “white” to best describe the stimulus was signiW-
cantly higher for all the tamoxifen users combined than for
control subjects (pD .012, likelihood ratio 2 D6.30, dfD1)
and (b) that the proportion was signiWcantly higher for long-
term tamoxifen users than for short-term-tamoxifen users
(pD .008, likelihood ratio 2 D6.94, dfD1). Altogether, the
results indicate that long-term tamoxifen use is associatedwith an increased likelihood of describing the threshold-level
440-nm stimulus as “white” in a forced-response paradigm
with “lavender” as the alternative.
The results in the preceding paragraph were derived
without regard for subjects’ prior exposures to chemother-
apy or radiation for breast cancer. However, an
Fig. 1. (A) Bar graph representing the proportions of subjects who
described the threshold-level 440-nm test stimulus as “lavender” (Wlled
bars) or “white” (unWlled bars). Data from the two subjects (one control
subject plus one short-term tamoxifen user) who described the stimulus as
“blue” are omitted for this Wgure, for reasons provided in the text. Thus,
the proportions are based on data from 31 control subjects, 29 short-term
tamoxifen users, and 24 long-term tamoxifen users. (B) Bar graph repre-
senting the proportions of subjects who described the suprathreshold-level
440-nm test stimulus as “lavender” (Wlled bars) or “white” (unWlled bars).
Data from the one subject (a control subject) who described the supra-
threshold test stimulus as “blue” are omitted for this Wgure, along with
data from the two subjects who described the threshold-level stimulus as
“blue”. Thus, the proportions are based on data from 30 control subjects,
29 short-term tamoxifen users, and 24 long-term tamoxifen users. The two
subjects who described the threshold-level stimulus as “blue” each
described the suprathreshold stimulus as “lavender”.
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long-term tamoxifen users did not become threshold-level
white-namers because of their prior cancer treatments.
When the threshold-level color-naming results from long-
term tamoxifen users who had not undergone chemother-
apy were compared directly with the corresponding results
from control subjects, the proportions of white-naming
subjects (13 of 15 vs. 12 of 29) remained signiWcantly
greater for tamoxifen users (p D 0.003, likelihood ratio
2 D 9.06, df D 1). Analogous results (9 of 11 vs. 13 of 30)
were obtained for subjects who had not undergone radia-
tion therapy (p D 0.023, likelihood ratio 2 D 5.13, df D 1).
For the fewer subjects who had undergone neither chemo-
therapy nor radiation, the comparison (6 of 8 vs. 12 of 28)
was non-signiWcant (p D 0.102, likelihood ratio 2 D 2.67,
df D 1).
The overall pattern of results changed somewhat when the
forced-response color-naming procedure was repeated with
the test stimulus set at 0.2 log units above threshold. The
color-naming results for the suprathreshold test stimulus are
graphed in Fig. 1B in the same manner as the corresponding
results for the threshold-level test stimulus in Fig. 1A. Data
from the one subject (a control subject) who chose “blue” to
best describe the suprathreshold stimulus are omitted from
Fig. 1B, as are data from the 2 subjects who chose “blue” to
best describe the threshold-level stimulus.
The color-naming diVerences among the three subject
groups were signiWcant for the suprathreshold stimulus
(p D 0.012, likelihood ratio 2 D 8.83, df D 2), as they were
for the threshold-level stimulus. Similarly, the proportion
of subjects who chose “white” to best describe the supra-
threshold stimulus was signiWcantly greater for all tamoxi-
fen users combined than for control subjects (p D 0.004,
likelihood ratio 2 D 8.50, df D 1). However, in contrast to
the threshold-level results, the proportion of subjects who
chose “white” to best describe the suprathreshold stimulus
was not signiWcantly higher for long-term tamoxifen users
than for short-term tamoxifen users (p D 0.567, likelihood
ratio 2 D 0.33, df D 1.) This negative result was obtained
largely because 7 short-term tamoxifen users who chose
“lavender” to best describe the threshold-level 440-nm
stimulus now chose “white” to best describe the supra-
threshold 440-nm stimulus. There was less change among
the other subject groups.
When the between-group comparisons for the supra-
threshold color-naming data were broken down on the
basis of prior treatment for breast cancer, only a single
comparison (control subjects vs. tamoxifen users, for
women not receiving radiation) was found to be even nom-
inally signiWcant (p < 0.05), with more white-namers among
the tamoxifen users. Surprisingly, all 5 lavender-naming
long-term tamoxifen users had received neither chemother-
apy nor radiation, whereas only 3 of the 19 white-naming
long-tamoxifen users had received neither chemotherapy
nor radiation. There is not enough information to deter-
mine whether this improbable result (p < 0.001) arose from
a recruitment bias or from an unknown confound.3.2. Comparisons of color-naming data with sensitivity data
Among control subjects, there appeared to be little to no
systematic relation of color-naming to sensitivity. For
example, when SWS-cone-mediated sensitivities for the 3.6
log td background were compared for white-namers vs. lav-
ender-namers after age-adjustment using an analysis of
covariance (ANCOVA), the resultant p values were 0.98 for
the threshold-level color-naming data and 0.37 for the
suprathreshold color-naming data. Similarly, there
appeared to be little to no systematic relation of color-nam-
ing to the degree of background-induced desensitization.
For example, consider the steady-state threshold elevation
induced by increasing background illuminance from 1.6 to
3.6 log td. When the mean threshold elevations were com-
pared for white- vs. lavender-namers using t tests (since
there was little eVect of age on these threshold elevations,
with r2 D 0.02), the resultant p values were 0.33 for the
threshold-level color-naming data and 0.88 for the supra-
threshold-level color-naming data. The overall mean
threshold elevation was 0.52 log units, averaging 0.56 and
0.50 log units for the threshold-level white-namers and the
threshold-level lavender-namers, respectively.
In contrast to the results for the control subjects, visual
sensitivities for the tamoxifen users were related to the
color-names used for best describing the suprathreshold
440-nm stimulus. More speciWcally, the choice of supra-
threshold color-name was related to diVerences in the abil-
ity of the visual system to adapt to backgrounds of diVerent
illuminances. These adaptation eVects were measured using
440-nm test stimuli that were conWrmed by spectral sensi-
tivity measurements to be detected via SWS cones on all
backgrounds for all but 4 subjects. For these 4 subjects (2
tamoxifen users plus 2 control subjects), the degree of SWS-
cone-isolation was uncertain for the dimmest background.
Thus, these subjects’ data have been excluded from all sta-
tistical analyses that include data obtained using this back-
ground.
The degree of threshold elevation (i.e., sensitivity reduc-
tion) that resulted from increasing the steady-state 580-nm
background illuminance from 1.6 to 3.6 log td is graphed in
Fig. 2 for all tamoxifen subjects. In Fig. 2A, the degree of
threshold elevation is graphed as a function of the duration
of tamoxifen use. In Fig. 2B, it is graphed as a function of
age. Open symbols represent subjects who chose “white” to
best describe the suprathreshold 440-nm test stimulus on the
3.6 log td 590-nm background, and Wlled symbols represent
subjects who chose “lavender”. The absence of any back-
ground-induced sensitivity loss for one subject is unusual but
not unprecedented (Eisner et al., 2004b). The 64-year-old
subject with the excessively high degree of background-
induced threshold elevation (see Fig. 2B) was the tamoxifen
user who used “blue” to best describe the threshold-level
440-nm test stimulus. Even with her data omitted from the
statistical comparison (since her SWS-cone response may not
have been isolated for the 1.6 log td background), tamoxifen
users who chose “white” to best describe the suprathreshold
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induced threshold elevation than tamoxifen users who chose
“lavender” to best describe this stimulus (pD0.026, t test). A
corresponding eVect that was statistically signiWcant
(pD 0.026) but small (»0.1 log unit) appeared to exist for the
threshold-elevation resulting from the increase of back-
ground illuminance from 1.6 to 2.0 log td.
The degree of background-induced threshold-elevation
did not diVer signiWcantly across the control subjects,
short-term tamoxifen users, and long-term tamoxifen
users. For example, the comparison between control sub-
jects and long-term tamoxifen users was non-signiWcant at
a nominal p value equal to 0.23 (t test). The comparisons
(after age correction) were weaker for threshold measure-
ments made for any single background illuminance. These
negative results can be interpreted to mean that color
naming was especially eVective for revealing eVects of
tamoxifen.
Fig. 2. (A) The threshold elevation at 440-nm caused by raising the illumi-
nance of the steady-state 580-nm background stimulus from 1.6 to 3.6 log
td, plotted as function of the duration of tamoxifen use. Open symbols
represent subjects who chose “white” to best describe the suprathreshold
440-nm test stimulus, and Wlled symbols represent subjects who chose
“lavender”. (B) Same as (A), except that the independent variable is age
rather than the duration of tamoxifen use.
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BThere was another set of negative results that was useful
for interpreting the data. With a 3.6 log td 580-nm back-
ground that isolates SWS-cone-mediated response at
490 nm, the diVerence of log sensitivity between 490 and
440 nm varies linearly with lens density (Eisner, Fleming,
Klein, & Mauldin, 1987). However, there was no suggestion
whatsoever that the lens densities of tamoxifen users
diVered from the lens densities of control subjects. When
the diVerence between the 2 groups was assessed using an
ANCOVA with age as the covariant, the resultant p value
equaled 0.81. (Not surprisingly, the age-eVect itself was sig-
niWcant at p D 0.001). This negative result indicates that the
color-naming diVerences between subject groups did not
result from age-related ocular media diVerences (Kraft &
Werner, 1999). Similarly, the 440-nm sensitivity data
obtained for 1.6 log td backgrounds (which are plausibly
assumed to cause the least sensitivity loss) gave no indica-
tion that either macular pigment or lens density diVerences
were important; an ANCOVA with age as the covariant
yielded a signiWcance level of p D 0.96 for the overall
between-group diVerence after correction for age.
4. Discussion
The results demonstrate that threshold measurements of
SWS-cone-mediated sensitivity may have only limited ability
for detecting changes in SWS-cone-mediated response that
may be subjectively apparent to subjects or to patients and
that, furthermore, can be used for documenting between-
group diVerences that are highly statistically signiWcant. In
addition, the results are consistent with the possibility that
changes in estrogen-receptor function can aVect the response
properties of SWS-cone pathways (Eisner et al., 2004b).
Estrogen receptors are present in the retina (Kobayashi,
Kobayashi, Ueda, & Honda, 1998; Munaut et al., 2001; Ogu-
eta, Schwartz, Yamashita, & Farber, 1999; Wickham et al.,
2000), but their roles for vision are unknown.
Because every tamoxifen user in our study had been diag-
nosed with hormone-positive breast cancer, we cannot
exclude the possibility that this form of breast cancer (or a
subtype of this form of breast cancer) led to an increased ten-
dency towards white-naming or shared a common antecedent
with this tendency. In other words, the data for this study can-
not logically distinguish an inherent disease-related eVect
from a medication eVect. However, we prefer the latter possi-
bility, as it is consistent with the rationale for the study and
several additional pieces of information. In particular, about
13% of tamoxifen users claim to experience vision changes
that they attribute to tamoxifen and that are strongly related
to serum tamoxifen levels and serum tamoxifen-metabolite
levels (Gallicchio et al., 2004). In addition, the duration-of-use
eVects we report are consistent with evidence for the ability of
tamoxifen to alter estrogen-receptor function within the cus-
tomary 5-year period of tamoxifen use (Ali & Coombes, 2002;
Ring & Dowsett, 2004). Nevertheless, because tamoxifen is
almost always administered after breast cancer has been
diagnosed, the confound between the breast-cancer history
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directly. An alternative strategy may be to investigate the
eVects of a closely related medication that can be studied pro-
spectively using non-correlational techniques. The fertility
medication clomiphene meets these criteria, as (a) it is a
SERM with a chemical structure very similar to that of
tamoxifen (Baker & JaVe, 1996), (b) it may cause reversible
visual disturbances (including prolonged afterimages) in up to
10% of patients under non-laboratory conditions (Fraunfel-
der & Fraunfelder, 2001), and (c) it is administered electively
to healthy women for a 5-day period (Baker & JaVe, 1996).
Empirically, the greatest background-induced thresh-
old elevations among tamoxifen users were found to
occur mostly among those subjects who described the
suprathreshold 440-nm stimulus as “lavender”. However,
the degree of background-induced threshold elevation
would be expected to be greatest for those subjects experi-
encing the greatest degree of background-induced
response polarization in a spectrally opponent SWS cone
pathway (Felius & Swanson, 2003; Pugh & Mollon, 1979).
For a yellow background, which increases LWS/MWS
cone stimulation, the direction of polarization (the L/M
direction) would be opposite to the direction of polariza-
tion (the S direction) resulting from increased SWS cone
stimulation in response to a 440-nm test. Thus, the
response in the S direction to the suprathreshold 440-nm
stimulus may often have been greatest for those subjects
for whom the response in the  L/M direction to the
580-nm background stimulus also was greatest. If so, the
gain and/or timing of responses in a spectrally opponent
SWS cone pathway may have been altered. Subsequent
studies can be designed to assess the role that hormonal
change or hormonal conditions may have for the short-
term dynamics of SWS-cone-mediated response (Shapiro,
Beere, & Zaidi, 2003) or for the diVerence between on- and
oV-responses to SWS cone stimulation (Klug, Herr, Ngo,
Sterling, & Schein, 2003; McLellan & Eskew, 2000; Shino-
mori et al., 1999; Vassilev, Mihaylova, Racheva, Zlatkova,
& Anderson, 2003).
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